Table 1.
Characteristics | Healthy subjects (n=35) | COPD patients (n=51) |
---|---|---|
Age (years) | 57±9 | 62±10* |
Sex, M/F | 14/21 | 33/18 |
Height (cm) | 169±8 | 169±10 |
Weight (kg) | 74±12 | 70±18 |
BMI (kg/m2) | 26±3 | 24±5 |
Tobacco status (NS/ExS/CS) | 14/0/8 | 0/26/25 |
Pack-year | 5 (0–42) | 44*** (10–125) |
FeNO (ppb) | 18 (6–39) | 13* (5–88) |
FEV1 pre (mL) | 2,986±763 | 1,517±630*** |
FEV1 pre (% pred) | 106±14 | 54±18*** |
FEV1 post (mL) | 3,199±885 | 1,658±701*** |
FEV1 post (%) | 113±15 | 59±20*** |
Reversibility (%) | 3±3 | 9±9** |
FVC pre (mL) | 3,799±968 | 2,796±924*** |
FVC pre (%) | 111±14 | 79±19*** |
FVC post (mL) | 3,807±1,113 | 2,951±990** |
FVC post (%) | 111±15 | 84±20*** |
FEV1/FVC pre (%) | 79±4 | 53±10*** |
FEV1/FVC post (%) | 84±4 | 55±10*** |
Oral corticosteroids | 0 (0%) | 6 (12%) |
Inhaled corticosteroids | 0 (0%) | 33 (65%) |
Inhaled corticosteroids (eg, beclomethasone/day) | 0 | 550*** (0–4,000) |
LABA | 0 (0%) | 39 (77%) |
Anticholinergics | 0 (0%) | 29 (57%) |
CAT total score | – | 21 (9–34) |
Notes: Data are presented as absolute number, absolute number (percentage), mean ± SD, or median (range).
P<0.05,
P<0.01,
P<0.001 vs healthy subjects.
Abbreviations: BMI, body mass index; NS, nonsmoker; ExS, ex-smoker; CS, current smoker; FeNO, fractional exhaled nitric oxide; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; pred, predicted; LABA, long-acting beta-agonist; CAT, COPD assessment test; SD, standard deviation; M, male; F, female.